Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia.

ABSTRACT: Patients with schizophrenia experience a broad range of detrimental health outcomes resulting from illness severity, heterogeneity of disease, lifestyle behaviors, and adverse effects of antipsychotics. Because of these various factors, patients with schizophrenia have a much higher risk of cardiometabolic abnormalities than people without psychiatric illness. Although exposure to many antipsychotics increases cardiometabolic risk factors, mortality is higher in patients who are not treated versus those who are treated with antipsychotics. This indicates both direct and indirect benefits of adequately treated illness, as well as the need for beneficial medications that result in fewer cardiometabolic risk factors and comorbidities. The aim of the current narrative review was to outline the

SUBMITTER: Meyer JM 

PROVIDER: S-EPMC10374807 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature